Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

OBJECTIVE The literature reports conflicting studies claiming premalignant histological features in benign ovaries from women who may have hereditary predilections for ovarian carcinoma. To test the veracity of these claims, this investigation studied ovaries prophylactically removed from members of hereditary breast ovarian cancer (HBOC) syndrome families who carry BRCA1 and BRCA2 mutations and compared these with the ovaries of mutation-negative women from the same HBOC syndrome kindred. METHODS Sixty cases of women from HBOC syndrome families who had undergone prophylactic oophorectomies and whose BRCA1 and BRCA2 mutation status had been tested were selected from our database. Thirty had tested positive for BRCA1 mutations, 3 carried BRCA2 mutations, and 27 were negative for both BRCA1 and BRCA2 germline mutations. Histologic material from each case was examined by light microscopy blinded to the mutation status. Histologic features, previously reported to be possible precursor lesions for ovarian cancer, were quantified. Data from BRCA1 and BRCA2 mutation carriers were compared with those from mutation-negative cases in the direct line of genetic inheritance from the same HBOC syndrome families. RESULTS Statistical analysis found that a more frequent occurrence of ovarian surface micropapillae in 87% of mutation carriers compared with just 55% of mutation-negative cases was the only histologic feature which was significantly different between the two groups (P = 0.39). Cortical clefts tended to be deeper in the ovaries of mutation carriers, but this did not reach significance (P = 0.051). There were no other significant histologic differences between the ovaries removed from mutation carriers and those from noncarriers. CONCLUSIONS The results of our large and prospectively controlled, blinded study contrast with those reported from smaller, unblinded investigations. Except for the possible biological significance of surface micropapillae on ovaries from BRCA1 and BRCA2 mutation carriers, we found no histologic evidence for a genetically determined ovarian carcinoma precursor lesion.

[1]  J Gil,et al.  Ovarian dysplasia in prophylactic oophorectomy specimens , 1999, Cancer.

[2]  D Lowe,et al.  Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Journal of the National Cancer Institute.

[3]  B. Werness,et al.  Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. , 1999, Human pathology.

[4]  B. Modan,et al.  Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. , 1998, Journal of the National Cancer Institute.

[5]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[6]  I. Petersen,et al.  Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome , 1997, Cancer.

[7]  D E Goldgar,et al.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. , 1997, American journal of human genetics.

[8]  A. Godwin,et al.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.

[9]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[10]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[11]  R. Kurman,et al.  BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT , 1995 .

[12]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[13]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[14]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[15]  J. Prat,et al.  Morphologic Precursors of Ovarian Epithelial Tumors , 1993, Obstetrics and gynecology.

[16]  H. Fox Pathology of early malignant change in the ovary. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[17]  H. Lynch,et al.  Hereditary Ovarian Cancer: A Clinicopathological Study , 1992, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[18]  G. Lenoir,et al.  Familial breast-ovarian cancer locus on chromosome 17q12-q23 , 1991, The Lancet.

[19]  H. Lynch,et al.  Hereditary ovarian cancer. Pedigree studies, Part II. , 1991, Cancer genetics and cytogenetics.

[20]  H. Lynch,et al.  Hereditary ovarian cancer. Heterogeneity in age at diagnosis , 1991, Cancer.

[21]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[22]  P. Dottino,et al.  Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. , 1990, Gynecologic oncology.

[23]  S. B. Gusberg,et al.  Ovarian dysplasia. A Study of identical twins , 1984, Cancer.

[24]  H. Lynch,et al.  Familial association of breast/ovarian carcinoma , 1978, Cancer.

[25]  J. Niloff,et al.  A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. , 1999, Obstetrics and gynecology.

[26]  P. Tonin,et al.  A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. , 1996, American Journal of Human Genetics.

[27]  M. Piver,et al.  Characteristics of familial ovarian cancer: a report of the first 1,000 families in the Gilda Radner Familial Ovarian Cancer Registry. , 1996, European journal of gynaecological oncology.

[28]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[29]  P. Russell Surface Epithelial—Stromal Tumors of the Ovary , 1994 .

[30]  A. Zeleniuch‐Jacquotte,et al.  Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. , 1993 .